The Life Sciences team advised Lacerta Therapeutics in its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of the collaboration, Prevail will receive rights to utilize one of Lacerta’s novel AAV capsids for select undisclosed CNS targets. In addition, Lacerta’s proprietary AAV capsid platform will be utilized to discover and develop novel AAV capsids that are optimized to target desired CNS tissues and cell types. The collaboration will leverage Lacerta’s established expertise in AAV technologies and Prevail’s development and clinical capabilities, with the goal of accelerating development of gene therapies for patients with neurodegenerative disorders.
Lacerta Therapeutics is a fully-integrated gene therapy company that is focused on leveraging its proprietary capsid technology and scalable manufacturing platforms to advance adeno-associated virus (AAV) based therapies via three primary approaches: gene replacement, gene modulation and novel vectorization of antibodies.
The Goodwin team was led by Emily Beman and included Noelle Dubiansky, Duncan Greenhalgh, Maria Smith, with invaluable assistance from Patty Shields.
For additional details on the collaboration, please read the press release.